Rutinib Cream

Rutinib Cream (also known as Opzelura) contains Ruxolitinib 1.5%, designed as a prescription treatment for mild to moderate eczema (atopic dermatitis) and vitiligo in patients aged 12 and above. As a topical JAK1/JAK2 inhibitor, Rutinib Cream works by reducing immune system overactivity, helping to alleviate inflammation, itching, and skin depigmentation. This effective treatment supports improved skin tone and texture with targeted use.

Uses:

• Treats mild to moderate eczema (atopic dermatitis) for quick itch relief
• Addresses skin discoloration and pigmentation loss due to vitiligo

Side Effects:

• Common side effects may include temporary redness or mild irritation at the application site.
• Rare side effects may include an increased risk of infections or heightened skin sensitivity.

Key Features:

• Contains Ruxolitinib (1.5%) for efficient symptom relief in eczema and vitiligo
• Known as Opzelura, providing a trusted option for skin inflammation and pigmentation issues
• Convenient cream format for targeted and easy application

References:

• Mayo Clinic, “Ruxolitinib Topical: Atopic Dermatitis and Vitiligo,” [Accessed on DATE], https://www.webmd.com/drugs/2/drug-182367/opzelura-topical/details
• U.S. Food and Drug Administration, “Opzelura (Ruxolitinib) Cream for Vitiligo and Eczema Treatment,” https://pmc.ncbi.nlm.nih.gov/articles/PMC10036407/